Medicare TRT Coverage: What Part D Pays, What It Refuses, and How to Cut Your Costs

How Medicare Classifies Testosterone Therapy

Medicare splits drug coverage between Part B (physician-administered drugs) and Part D (self-administered drugs), and testosterone falls into both buckets depending on how it is given. Self-injected testosterone cypionate or enanthate, topical gels, and transdermal patches are Part D drugs. Testosterone pellets inserted in a physician office and intramuscular injections administered by a nurse are Part B drugs because a clinician administers them.

Part D plans are run by private insurers under CMS contracts, so formulary placement varies by plan. Most Part D formularies place generic testosterone cypionate on Tier 1 or Tier 2, meaning a 30-day supply costs $10, $47 after the deductible phase. Brand-name formulations such as Androgel 1.62% (testosterone gel) or Xyosted 75 mg/0.5 mL (testosterone enanthate auto-injector) typically land on Tier 3 or Tier 4, where cost-sharing runs $50, $120 per fill on standard plans. The FDA approved Xyosted in 2018 specifically as a subcutaneous weekly injection, which some patients prefer to intramuscular cypionate. FDA approval record for Xyosted.

Part B coverage of physician-administered testosterone requires the injection to occur in a Medicare-participating outpatient setting. After the 20% Part B coinsurance and any deductible, the patient's share for a quarterly Aveed (testosterone undecanoate) injection is typically $30, $90 per visit depending on the supplemental (Medigap) policy in place. FDA labeling for Aveed.

The Diagnostic Requirements Medicare Enforces

Coverage requires a confirmed diagnosis of hypogonadism. Medicare does not cover testosterone for age-related decline without a diagnosable condition. Two separate serum total testosterone measurements below roughly 300 ng/dL, drawn in the morning before 10 a.m. and after at least one hour of fasting, are the standard documentation most Part D plans and Medicare Advantage plans demand before authorizing a claim. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism specifies this two-measurement standard and sets 300 ng/dL as the lower limit of the normal reference range. Endocrine Society 2018 guideline.

Free testosterone measurement adds diagnostic weight when total testosterone sits in the 300 to 400 ng/dL borderline range, particularly in men with obesity or altered sex hormone-binding globulin. The guideline notes that free testosterone <65 pg/mL (calculated by Vermeulen equation) supports the hypogonadism diagnosis when total testosterone is ambiguous. Bhasin S et al., J Clin Endocrinol Metab 2018.

The treating physician must also document at least one clinical symptom: reduced libido, erectile dysfunction, decreased energy, depressed mood, reduced muscle mass, or osteoporosis. Plans increasingly require the ICD-10 code E29.1 (testicular hypofunction) or E23.0 (hypopituitarism-related hypogonadism) on the prescription. A claim submitted with only a "low testosterone" narrative note, without a coded diagnosis and two qualifying labs, is almost always denied on first submission.

Prior Authorization: Step-by-Step Process for Medicare Part D

Prior authorization (PA) is required by the vast majority of Medicare Part D plans for testosterone products, particularly name-brand gels and auto-injectors. The process typically takes 3, 10 business days and follows a predictable sequence.

Step 1. The prescribing physician or their office submits a PA request to the plan's pharmacy benefit manager (PBM), attaching the two qualifying testosterone lab reports with collection timestamps, the relevant ICD-10 diagnosis code, and a brief clinical note describing symptoms.

Step 2. The PBM reviews against the plan's coverage criteria. Generic testosterone cypionate PA criteria are usually satisfied by the two labs plus diagnosis code alone. Brand-name products often require step therapy, meaning the plan wants documentation that the patient tried generic cypionate first and either had an adverse reaction or a clinical reason precluding its use.

Step 3. If denied, the physician files a formal appeal. First-level appeals must be decided within 72 hours for standard reviews or 24 hours for expedited reviews under 42 CFR 423.590. CMS Medicare Part D appeals regulations.

Step 4. If the first appeal fails, an Independent Review Entity (IRE) contracted by CMS conducts a second-level review. IRE overturn rates for testosterone PAs are not publicly broken out, but the broader Medicare Part D IRE upholds enrollee requests in approximately 40% of cases reviewed. CMS Part D Appeals Data 2023.

Physicians should attach the Endocrine Society guideline reference and any relevant symptom scoring (AMS scale or IIEF score) to the appeal letter. Plans rarely override a well-documented appeal with two confirming labs and a guideline-concordant clinical note.

What Medicare Advantage Plans Do Differently

Medicare Advantage (Part C) plans must cover everything original Medicare covers, but they administer benefits through their own formularies and utilization-management rules. In practice, a United Healthcare AARP Medicare Advantage plan may have a more restrictive testosterone PA checklist than a Humana PPO plan in the same county.

Key differences compared to original Medicare plus a standalone Part D plan include tighter step-therapy requirements (some Advantage plans mandate a 90-day trial of lifestyle modification before approving TRT), narrower pharmacy networks (mail-order preferred pricing may cut copays by 30%), and prior authorization criteria that sometimes require a specialist note from an endocrinologist or urologist rather than a primary care attestation alone.

The American Urological Association 2022 testosterone therapy guidelines state: "Clinicians should counsel patients with testosterone deficiency regarding the benefits, risks, and alternatives to testosterone therapy." AUA 2022 testosterone guidelines. Getting a urologist or endocrinologist involved early accelerates PA approval on Advantage plans because the specialist note satisfies the credential-based criteria many plans impose.

Real 2025 TRT Costs: What You Pay With and Without Medicare

Generic testosterone cypionate 200 mg/mL, 10 mL vial. Cash price at major chain pharmacies: $30, $60. With Part D Tier 1 coverage after deductible: $0, $15. Annual cost on Part D: roughly $120, $180 for medication alone.

Testosterone enanthate (Xyosted 75 mg/0.5 mL, 4-week supply). Cash price: $550, $650. With Part D Tier 3 coverage: $50, $120 per month. Annual cost on Part D: $600, $1,440.

Androgel 1.62% (testosterone gel, 30-pump canister). Cash price: $400, $600 per month. Generic testosterone gel 1.62% cash price: $80, $140. With Part D Tier 2 coverage on generic: $15, $47 per month.

Testosterone pellets (Testopel). Pellets themselves are billed under Part D when the patient self-procures, but in practice the pellet insertion procedure is the dominant cost. Part B covers the insertion under CPT 11980 if done in a participating outpatient setting; the 20% coinsurance on a $400, $600 procedure yields $80, $120 per insertion, typically needed every 3 to 6 months.

Lab monitoring is a separate line item. Medicare Part B covers serum testosterone testing (CPT 84402 or 84403) when ordered for a covered diagnosis. A baseline panel including total testosterone, LH, FSH, hematocrit, and PSA is fully covered under Part B after the annual deductible ($240 in 2025). CMS 2025 Part B deductible fact sheet.

The table below summarizes the cost framework across coverage scenarios.

| Formulation | Cash (no coverage) | Part D Tier 1, 2 | Part D Tier 3, 4 | Part B (office-admin) | |---|---|---|---|---| | Testosterone cypionate (generic) | $30, $60/vial | $0, $15/mo | N/A | N/A | | Xyosted 75 mg auto-injector | $550, $650/mo | N/A | $50, $120/mo | N/A | | Androgel 1.62% (generic gel) | $80, $140/mo | $15, $47/mo | N/A | N/A | | Aveed (undecanoate injection) | $1,200+/dose | N/A | N/A | 20% of allowed amount | | Testopel pellets (insertion) | $400, $600/procedure | Pellets ~$100, $200 | N/A | 20% of insertion fee |

How Online TRT Clinics Price Their Services vs. Medicare Coverage

Online TRT telehealth providers such as Hone Health, Maximus, and Defy Medical price their services as membership or monthly subscription models. These typically run $99, $199 per month and include the physician consultation and prescription, but not the cost of labs or the medication itself. Labs add $75, $150 per draw, and medication adds $30, $60 for generic cypionate.

Medicare does not cover telehealth TRT services in the same way private insurance does. A Medicare-enrolled physician can prescribe testosterone via telehealth, and the Part D claim for the drug is processed normally, but the telehealth visit fee is subject to Medicare Part B rules. Since 2020, CMS has expanded telehealth flexibility, and as of 2025, Medicare covers hormone-related telehealth consultations when the beneficiary has a confirmed hypogonadism diagnosis. CMS telehealth coverage fact sheet 2025.

Men on Medicare who use a cash-pay online TRT clinic should be aware that providers who opt out of Medicare cannot bill Part B for the consultation. The drug claim through Part D is unaffected because the pharmacy, not the physician, submits it. This means a patient can see a cash-pay telehealth provider, get a prescription, and still use their Part D benefit at a participating pharmacy.

The Testosterone Therapy Efficacy Data Medicare Reviewers Look At

Medicare coverage decisions reference clinical evidence. The T-Trials (Testosterone Trials, N=788 men aged 65 and older with confirmed hypogonadism) published in NEJM in 2016 showed that testosterone treatment for one year improved sexual function scores by a mean of 2.4 points on the PDAS scale (P<0.001) and improved bone density at the lumbar spine by 7.5% compared to placebo. Snyder PJ et al., NEJM 2016.

The same T-Trials data published in JAMA Internal Medicine showed a statistically significant improvement in walking distance (mean 40 meters vs. 12 meters in placebo, P=0.01) and mood as measured by the PHQ-9 scale. Resnick SM et al., JAMA Intern Med 2017.

On cardiovascular risk, the TRAVERSE trial (N=5,246 men with hypogonadism and elevated cardiovascular risk) published in NEJM in 2023 found that testosterone gel 1.62% did not increase major adverse cardiovascular events compared to placebo over a mean follow-up of 33 months (7.0% testosterone vs. 7.3% placebo, non-inferiority met). Lincoff AM et al., NEJM 2023. This trial substantially changed the risk-benefit conversation Medicare reviewers and plans use when evaluating coverage requests.

Prior to TRAVERSE, many Part D plans cited cardiovascular risk as grounds for non-coverage in older men. Post-TRAVERSE, cardiovascular risk alone is no longer a standard denial basis in a man with confirmed hypogonadism below 300 ng/dL. Physicians appealing denials on cardiovascular grounds should cite Lincoff et al. directly in the appeal letter.

Strategies to Reduce Out-of-Pocket Costs on Medicare

Choose generic testosterone cypionate first. At $30, $60 per vial with a 10-week supply in a typical 100 mg/week protocol, annual medication cost is $156, $312 cash, and far less on Part D. Most clinical outcomes data, including the T-Trials, used injectable testosterone rather than gel.

Use a Medicare Savings Program if income-eligible. The Low Income Subsidy (LIS, also called "Extra Help") eliminates or reduces Part D premiums, deductibles, and copays for beneficiaries below 150% of the federal poverty level. In 2025, that threshold is $21,978 for a single person. Under full LIS, testosterone cypionate costs $0, $4.50 per fill. CMS Extra Help program.

Enroll in a Part D plan that places generic testosterone on Tier 1. Use the Medicare Plan Finder at medicare.gov during open enrollment (October 15 to December 7) and filter by your ZIP code and the specific drug NDC for testosterone cypionate 200 mg/mL. Plans vary by $200, $800 per year in total drug cost for the same generic.

Use an HSA or FSA if transitioning from employer coverage to Medicare. HSA contributions stop at Medicare enrollment, but existing balances can be used for Medicare premiums and out-of-pocket drug costs tax-free. A man who retires at 65 with $8 to 000 in an HSA can cover two to three years of TRT medication and labs from that pre-tax account.

Ask the prescriber about GoodRx or Mark Cuban's Cost Plus Drugs. These cash-pay discount programs are not usable alongside Medicare Part D for the same prescription in the same coverage period, but men in the Part D coverage gap (donut hole) may find cash prices lower than their gap-phase cost sharing. In 2025, the Inflation Reduction Act capped out-of-pocket Part D spending at $2,000 annually, which largely eliminates the donut hole problem for most TRT users given the low cost of generic testosterone. CMS IRA Part D redesign 2025.

Special Situations: Secondary Hypogonadism and Cancer Survivors

Secondary hypogonadism (low testosterone caused by pituitary or hypothalamic dysfunction) has a distinct ICD-10 code, E23.0, and Medicare coverage criteria are the same: two morning testosterone draws below 300 ng/dL plus a clinical diagnosis. Men who developed hypogonadism after opioid therapy (opioid-induced androgen deficiency) may document OIAD with the prescribing record as supporting evidence. Brennan MJ, J Pain Symptom Manage 2013.

Prostate cancer survivors present a more complex coverage situation. Most Part D plans exclude TRT for men with active or recently treated prostate cancer. The AUA 2022 guideline notes that testosterone therapy may be offered to carefully selected hypogonadal men after prostate cancer treatment under shared decision-making, but coverage is not guaranteed and requires a urologic oncology note. Men in this group typically pay cash for TRT, with costs of $30, $60 per month for generic injectable testosterone.